Evidence-Based Reviews

E-cigarettes and vapes: Do they work for smoking cessation and should we be recommending their use?

Current Psychiatry. 2017 May;16(5):30-34,36-39

References

1. Hajek P, Goniewicz ML, Phillips A, et al. Nicotine intake from electronic cigarettes on initial use and after 4 weeks of regular use. Nicotine Tob Res. 2015;17(2):175-179.
2. Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf. 2014;5(2):67-86.
3. St Helen G, Havel C, Dempsey DA, et al. Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. Addiction. 2016;111(3):535-544.
4. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. Circulation. 2014;129(19):1972-1986.
5. Zhu SH, Sun JY, Bonnevie E, et al. Four hundred and sixty brands of e-cigarettes and counting: implications for product regulation. Tob Control. 2014;23(suppl 3):iii3-iii9. doi: 10.1136/tobaccocontrol-2014-051670.
6. Schoenborn CA, Gindi RM. Electronic cigarette use among adults: United States, 2014. NCHS Data Brief. 2015;(217):1-8.
7. Farsalinos KE, Poulas K, Voudris V, et al. Electronic cigarette use in the European Union: analysis of a representative sample of 27 460 Europeans from 28 countries. Addiction. 2016;111(11):2032-2040.
8. Cummins SE, Zhu SH, Tedeschi GJ, et al. Use of e-cigarettes by individuals with mental health conditions. Tob Control. 2015;23(suppl 3):iii48-iii53. doi: 10.1136/tobaccocontrol-2013-051511.
9. Spears CA, Jones DM, Weaver SR, et al. Use of electronic nicotine delivery systems among adults with mental health conditions, 2015. Int J Environ Res Public Heal. 2017;14(1):10.
10. Hefner K, Valentine G, Sofuoglu M. Electronic cigarettes and mental illness: reviewing the evidence for help and harm among those with psychiatric and substance use disorders [published online February 2, 2017]. Am J Addict. doi: 10.1111/ajad.12504.
11. Anthenelli R. How—and why—to help psychiatric patients stop smoking. Current Psychiatry. 2005;4(1):77-87.
12. Singh T, Arrazola RA, Corey CG, et al. Tobacco use among middle and high school students—United States, 2011-2015. MMWR Morb Mortal Wkly Rep. 2016;65(14):361-367.
13. Greenhill R, Dawkins L, Notley C, et al. Adolescent awareness and use of electronic cigarettes: a review of emerging trends and findings. J Adolesc Heal. 2016;59(6):612-619.
14. U.S. Department of Health and Human Services. E-cigarette use among youth and young adults: a report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2016.
15. Cooper M, Harrell MB, Pérez A, et al. Flavorings and perceived harm and addictiveness of e-cigarettes among youth. Tob Regul Sci. 2016;2(3):278-289.
16. Kim H, Davis AH, Dohack JL, et al. E-cigarettes use behavior and experience of adults: qualitative research findings to inform e-cigarette use measure development. Nicotine Tob Res. 2017;19(2):190-196.
17. Czoli CD, Fong GT, Mays D, et al. How do consumers perceive differences in risk across nicotine products? A review of relative risk perceptions across smokeless tobacco, e-cigarettes, nicotine replacement therapy and combustible cigarettes. Tob Control. 2017;26(e1):e49-e58.
18. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet. 2013;382(9905):1629-1637.
19. Caponnetto P, Campagna D, Cibella F, et al. EffiCiency and safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013;8(6):e66317. doi: 10.1371/journal.pone.0066317.
20. Adriaens K, Van Gucht D, Declerck P, et al. Effectiveness of the electronic cigarette: an eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaints. Int J Environ Res Public Health. 2014;11(11):11220-11248.
21. Tseng TY, Ostroff JS, Campo A, et al. A randomized trial comparing the effect of nicotine versus placebo electronic cigarettes on smoking reduction among young adult smokers. Nicotine Tob Res. 2016;18(10):1937-1943.
22. Meier E, Wahlquist AE, Heckman BW, et al. A pilot randomized crossover trial of electronic cigarette sampling among smokers. Nicotine Tob Res. 2017;19(2):176-182.
23. Hartmann-Boyce J, McRobbie H, Bullen C, et al. Electronic cigarettes for smoking cessation [published online September 14, 2016]. Cochrane Database Syst Rev. 2016;9:CD010216.
24. Biener L, Hargraves JL. A longitudinal study of electronic cigarette use among a population-based sample of adult smokers: association with smoking cessation and motivation to quit. Nicotine Tob Res. 2014;17(2):127-133.
25. Etter JF, Bullen C. A longitudinal study of electronic cigarette users. Addict Behav. 2014;39(2):491-494.
26. Caponnetto P, Auditore R, Russo C, et al. Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health. 2013;10(2):446-461.
27. Popova L, Ling PM. Alternative tobacco product use and smoking cessation: a national study. Am J Public Health. 2013;103(5):923-930.
28. Adkison SE, O’Connor RJ, Bansal-Travers M, et al. Electronic nicotine delivery systems: International Tobacco Control Four-Country Survey. Am J Prev Med. 2013;44(3):207-215.
29. Brose LS, Hitchman SC, Brown J, et al. Is the use of electronic cigarettes while smoking associated with smoking cessation attempts, cessation and reduced cigarette consumption? A survey with a 1-year follow-up. Addiction. 2015;110(7):1160-1168.
30. Manzoli L, Flacco ME, Ferrante M, et al; ISLESE Working Group. Cohort study of electronic cigarette use: effectiveness and safety at 24 months [published online June 6, 2016]. Tob Control. doi: 10.1136/tobaccocontrol-2015-052822.
31. Lerner CA, Sundar IK, Yao H, et al. Vapors produced by electronic cigarettes and E-juices with flavorings induce toxicity, oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung. PLoS One. 2015;10(2):e0116732. doi: 10.1371/journal.pone.0116732.
32. Sussan TE, Gajghate S, Thimmulappa RK, et al. Exposure to electronic cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model. PLoS One. 2015;10(2):e0116861. doi: 10.1371/journal.pone.0116861.
33. US Environmental Protection Agency. Acrolein. https://www.epa.gov/sites/production/files/2016-08/documents/acrolein.pdf. Updated September 2009. Accessed April 7, 2017.
34. Vardavas CI, Anagnostopoulos N, Kougias M, et al. Short-term pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric oxide. Chest. 2012;141(6):1400-1406.
35. Etter JF. Electronic cigarettes: a survey of users. BMC Public Health. 2010;10:231.
36. Goniewicz ML, Lingas EO, Hajek P. Patterns of electronic cigarette use and user beliefs about their safety and benefits: an internet survey. Drug Alcohol Rev. 2013;32(2):133-140.
37. Laino T, Tuma C, Moor P, et al. Mechanisms of propylene glycol and triacetin pyrolysis. J Phys Chem A. 2012;116(18):4602-4609.
38. Brook RD, Rajagopalan S, Pope CA 3rd, et al; American Heart Association Council on Epidemiology and Prevention; Council on the Kidney in Cardiovascular Disease; Council on Nutrition, Physical Activity and Metabolism. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation. 2010;121(21):2331-2378.
39. Barrington-Trimis JL, Samet JM, McConnell R. Flavorings in electronic cigarettes: an unrecognized respiratory health hazard? JAMA. 2014;312(23):2493-2494.
40. Schripp T, Markewitz D, Uhde E, et al. Does e-cigarette consumption cause passive vaping? Indoor Air. 2013;23(1):25-31.
41. Fuoco FC, Buonanno G, Stabile L, et al. Influential parameters on particle concentration and size distribution in the mainstream of e-cigarettes. Environ Pollut. 2014;184:523-529.
42. Schober W, Szendrei K, Matzen W, et al. Use of electronic cigarettes (e-cigarettes) impairs indoor air quality and increases FeNO levels of e-cigarette consumers. Int J Hyg Environ Health. 2014;217(6):628-637.
43. Bhatnagar A, Whitsel L, Ribisl K, et al; American Heart Association Advocacy Coordinating Committee; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Quality of Care and Outcomes Research. Electronic cigarettes: a policy statement from the American Heart Association. Circulation. 2014;130(16):1418-1436.
44. E-cigarettes pose risks. SAMHSA News. https://www.samhsa.gov/samhsaNewsLetter/Volume_22_Number_3/e_cigarettes. Published 2014. Accessed April 7, 2017.
45. National Institute on Drug Abuse. Electronic cigarettes (e-cigarettes). https://www.drugabuse.gov/publications/drugfacts/electronic-cigarettes-e-cigarettes. Revised May 2016. Accessed April 7, 2017.
46. American Academy of Addiction Psychiatry. Nicotine dependence. East Providence, RI: American Academy of Addition Psychiatry; 2015.
47. Green SH, Bayer R, Fairchild AL. Evidence, policy, and e-cigarettes — will England reframe the debate. N Engl J Med. 2016;374(14):1301-1303.
48. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014;311(2):193-194.

Recommendations from agencies and medical organizations

The World Health Organization (WHO) recommended prohibiting the use of ENDS in indoor spaces to minimize potential health risks to users and non-users. The WHO also aims to prevent dissemination of unproven health claims, including claims that ENDS are effective—or not—or that the devices are innocuous.³⁶ In the United States, the FDA has stated that ENDS are not recommended for safe quitting (2009). In August 2016, the FDA introduced regulations banning the sale of ENDS to individuals age <18 and required manufacturers to submit documents detailing all ingredients for review and possible approval.

The American Lung Association has stated its concerns about the use of ENDS but has not made any direct recommendations. The American Heart Association reports a potential negative public health impact and provides clinical guideline recommendations.⁴³ Prominent psychiatric organizations such as the American Psychiatric Association, American Academy of Addiction Psychiatry (AAAP), the Substance Abuse and Mental Health Services Administration (SAMHSA), and the National Institute of Drug Abuse do not have official statements supporting or rejecting the use of ENDS. However, they do note the potential harm and lack of substantial evidence for efficacy of ENDS as a smoking cessation tool, and the AAAP and SAMHSA state that they will work with regulatory agencies to reduce the use of toxic products with addictive potential including ENDS.^44-46

Clinical recommendations

We do not recommend ENDS as a first-line treatment for smoking cessation because there is no evidence they are superior to the FDA-approved nicotine replacement therapies (NRTs), the paucity of research into the potential short- and long-term health risks of ENDS, and the fact that these products are not regulated for use as smoking cessation aids. It is, however, advisable to discuss ENDS use with patients by:

asking if they are using the products
assessing whether the user also is a smoker
advising the patient to quit.

It also is important to assess the patient’s knowledge and attitudes regarding ENDS use and provide education about the products. Some patients firmly believe that ENDS are the lesser of 2 evils, and they are decreasing the harms of smoking by using these devices. While the debate over a potential harm reduction strategy unfolds,⁴⁷ we think that because of the state of the evidence it is prudent to adopt a more precautionary stance and recommend that patients work toward abstinence from nicotine in any form.

For dual tobacco/ENDS users and for patients using ENDS who want to quit smoking, we recommend treatment with an approved pharmacotherapy (ie, NRTs, bupropion, and varenicline) combined with counseling. A 2013 Cochrane Review found that all pharamacotherapy options are more effective than placebo, and combination NRT and varenicline are superior to single NRT or bupropion (Box).^23,48

Bottom Line

Many individuals use electronic nicotine delivery systems (ENDS) as a smoking cessation aid or because they think the devices are safer than tobacco cigarettes. However, because of the paucity of evidence regarding their efficacy as smoking cessation aids and concerns raised about their short- and long-term health consequences, we do not recommend using ENDS in psychiatric patients who smoke. The role these products may play in harm reduction remains to be seen.

E-cigarettes and vapes: Do they work for smoking cessation and should we be recommending their use?

References

Recommendations from agencies and medical organizations

Clinical recommendations

Bottom Line

Pages

Recommended Reading